That strategy has worked well, Cramer noted, as Carrizo has now overcome its funding gap and can now fund operations through 2014.
Johnson cited the Niobara shale field in Colorado as one of Carrizo's many untapped assets. He said the region is just getting started but so far has been very profitable. Meanwhile, his company has been selling some of its Barnett shale assets as those wells have been primarily producing dry gas, which is not Carrizo's strong suit.
When asked about the possibility of being acquired, Johnson said that every small producer is being studied by larger companies, but he remains focused on growing and establishing his company's acreage and is not pay attention to possible acquisitions.
Cramer said Carrizo remains a great growth story and he remains a believer in the stock.
More Anointed Stocks
Continuing with his "Anointed Stock" series, Cramer looked at the best-performing biotech stocks of the year with the help of colleague Bob Lang for some technical analysis.
First, Lang looked at
(CELG - Get Report)
, a stock that's been running since mid-August on high volume. Lang felt that with the MACD and Williams' oscillators both showing an embedded overbought condition, this stock would rally hard through the end of the year, after first pulling back to its 50-day moving average of $140.
Next, Lang looked at
(REGN - Get Report)
, which after rallying from $170 to $300 a share broke out over a double top to continue to new all-time highs. Lang noted the RSI and Williams' oscillators also showed strong overbought conditions, making this stock a buy after it pulls back to its floor of support at $275 a share.
Then there was
(GILD - Get Report)
, which Lang said had the best trend line of the bunch. Lang felt this stock could be bought even without a pullback.
In the Lightning Round, Cramer was bullish on
Cramer was bearish on
Executive Decision: Jean-Jacques Bienaime
In the "Executive Decision" segment, Cramer spoke with Jean-Jacques Bienaime, CEO of
(BMRN - Get Report)
, the orphan-drug maker whose four drugs have already racked up over $500 million in sales thanks, in part, to their high price tags of between $95,000 and $350,000 a year. Shares of BioMarin are up 28% since Cramer last featured the company in June.
Bienaime explained that with orphan drug makers it's not about the number of patients who you treat, it's about improving the quality of life for those you do. He said the patient populations they serve run between just 200,000 patients in the U.S. down to just 10,000 patients. But with no other alternative treatments available, insurance companies are willing to pay the drug's big premium since it makes such a huge difference.
Bienaime also touted his company's fifth drug, which is currently in Phase III testing, as a game changer for BioMarin because that drug also could more than double the company's revenue.
When asked about the scores of patients who are literally dying to get into new drug trials and studies, Bienaime said BioMarin works to get effective and safe drugs onto the market as quickly as possible, but it can't always accept new patients into their studies because they require randomized samples and double-blind studies.
Cramer called BioMarin one of the strongest biotech stories out there and one investors need to investigate.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer threw up his hands and said it's time to surrender all hope that Washington will ever understand the potential of oil and natural gas in our country. "How can this be so hard?" he asked.
Nearly all of the objections to natural gas have been met or debunked, Cramer continued. Yet, you'll be hard-pressed to find any elected official who's not on the renewable energy bandwagon touting solar and ethanol rather than stopping oil and gas imports from hostile nations.
Cramer said it's almost as if Congress has declared war on gaining energy independence and is now seeing higher gas prices as an incentive to conserve. Renewable energy, he concluded, is like a religion in Washington that cannot be stopped.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,